Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to 2033" report has been added to ResearchAndMarkets.com's offering.
The influenza vaccines market in the United States has experienced significant growth in recent years, driven by various factors including heightened public awareness of infectious diseases and the ongoing innovations in vaccine technology.
As of 2024, the market is estimated to be valued at approximately US$ 4.78 billion, reflecting a positive trajectory in terms of demand and accessibility. This growth is expected to continue, with projections indicating that the market could reach around US$ 9.66 billion by 2033, representing a compound annual growth rate (CAGR) of approximately 8% from 2025 - 2033.
A key contributor to this upward trend is the increasing incidence of influenza outbreaks and the resulting need for immunization among diverse demographics. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of vaccination, which, combined with government initiatives promoting vaccine accessibility, is vital for maintaining public health standards. Additionally, advancements in vaccine formulation, including the development of quadrivalent vaccines that protect against four strains of influenza, are anticipated to enhance market appeal, further driving vaccination rates.
Moreover, the United States has seen an influx of new players in the influenza vaccines sector, alongside traditional manufacturers, leading to increased competition and innovation. The landscape of the industry is increasingly shaped by strategic partnerships and collaborations, aimed at enhancing research and development capabilities. As more organizations engage in the production of influenza vaccines, the competition is likely to yield a greater variety of vaccine options available to consumers, thereby expanding the market.
Technological advancements, particularly in the field of mRNA vaccines, are further changing the dynamics of vaccine development. The successful deployment of mRNA technology during the COVID-19 pandemic has opened opportunities for similar approaches in the influenza vaccine space. These advancements are expected to enhance immunogenicity and reduce the time needed for vaccine development, thereby positioning the market for accelerated growth in the coming years. Overall, the United States influenza vaccines market is on an upward path, bolstered by enhanced awareness, innovation, and strategic collaborations.
Latest Trends in the United States Influenza Vaccines Market
The landscape of the influenza vaccine market is undergoing significant transformation, driven by various emerging trends. One of the most notable advancements is in vaccine technology. Innovations such as mRNA technology, previously spotlighted during the COVID-19 pandemic, have gained attention in the realm of influenza vaccination. These advancements aim to enhance the efficacy and speed of vaccine development, potentially leading to more effective annual vaccines tailored to evolving virus strains.
Another significant trend is the increasing demand for personalized medicine in vaccine administration. With an escalating understanding of genetic variations among individuals, there is a push towards developing personalized vaccines which align with individual immune profiles. This tailored approach not only maximizes the likelihood of immune response but also minimizes potential adverse effects, thereby increasing the overall vaccination uptake.
Public perception is also shifting, with growing acceptance of various vaccine formulations including quadrivalent and high-dose vaccines. The increase in awareness through public health campaigns and educational initiatives has led to a more informed populace that is open to receiving influenza vaccines. However, challenges persist, including vaccine hesitancy spurred by misinformation and skepticism surrounding vaccine safety. Addressing these concerns is crucial for health authorities and providers to bolster vaccine acceptance.
Moreover, factors such as age demographics and health status significantly influence vaccine uptake trends. The growing elderly population, coupled with rising chronic illnesses among younger individuals, creates an urgent need for effective influenza preventive measures, highlighting the importance of vaccination. As research continues to shed light on these trends, understanding them will be critical for stakeholders aiming to navigate the future landscape of the influenza vaccine market successfully.
United States Influenza Vaccines Market Competitive Landscape
The influenza vaccines market in the United States is characterized by the presence of several key players, each contributing to the competitive landscape through distinct strategies and market shares. The leading manufacturers include prominent pharmaceutical companies such as GlaxoSmithKline, Sanofi Pasteur, AstraZeneca and Seqirus, which together dominate a significant portion of the market.
The competitive strategies employed by manufacturers, including pricing models, promotional activities, and collaborations with healthcare entities, are instrumental in shaping the dynamics of the influenza vaccines market in the United States.
Scope of the Report
- The United States influenza vaccine market: size, insights, analysis and forecast, 2019 - 2033
- Number of people vaccinated with influenza vaccines in the United States and forecast, 2019 - 2033
- Analyzes children in the United States vaccinated with influenza vaccines and projections, 2019 - 2033
- Analyzes adults in the United States who are vaccinated with influenza vaccines and predicts 2019 - 2033
- Key growth drivers and challenges of the influenza vaccine market in the United States
- The United States influenza vaccines price analysis, trends and insights
- Production, supply and distribution of influenza vaccines in the United States (by company)
- The United States flu vaccines distribution and demand analysis
- Impact of vaccination effectiveness and diagnostics
- Thoroughly assesses of the distribution channel and technique of the influenza vaccination in the United States
- Reimbursement environment in the influenza vaccines market in the United States
- Regulatory outline of the United States influenza vaccines market
- Important deals and agreements in the influenza vaccines market
- An insightful analysis of promising influenza vaccines in clinical development
- Examine the most latest clinical trials of the influenza vaccines
- An all-inclusive list of the key players along with the analysis of their current vaccines portfolios, promising vaccines in the clinical development, influenza vaccines market value, and recent development
- An insightful analysis of the emerging players along with the analysis of their promising vaccines in the clinical development, phase, platform technology, and recent development
Top and Emerging Player's Profiles
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax
- Medicago
- Moderna Inc
- Pneumagen
- Daiichi-Sankyo
- Altimmune
- FluGen
- Imutex
- EpiVax, Inc
- Versatope Therapeutics, Inc
- BiondVax Pharmaceuticals Ltd.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 230 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $4.78 Billion |
| Forecasted Market Value (USD) by 2033 | $9.66 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | United States |
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. United States Influenza Vaccines Market Size, Insights, Analysis, and Forecasts (2019 - 2033)
5. United States Number of Persons Vaccinated with Influenza Vaccines (2019 - 2033)
5.1 Number of Children Vaccinated with Influenza Vaccines
5.2 Number of Adults Vaccinated with Influenza Vaccines
6. Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
6.1 Market Drivers
6.2 Market Challenges
7. United States Influenza Vaccines Pricing Analysis, Trends and Insights
8. United States Influenza Vaccines Production, Supply, and Allocation (By Companies),2014 - 2024
9. United States Influenza Vaccines Distribution and Demand Analysis 2010 - 2024
10. Effectiveness of Influenza Vaccines in the United States, 2004 - 2024
11. Rapid Diagnostic Testing for the Management of Influenza
12. Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States
13. Reimbursement Environment of the United States Influenza Vaccines Market
14. Regulatory Framework of the United States Influenza Vaccines Market
15. Major Deals and Agreement Activities in the Influenza Vaccines Market
15.1 Merger and Acquisitions
15.2 Collaboration Deals
15.3 Licensing Agreement
15.4 Exclusive Agreement
15.5 Distribution Agreement
16. Promising Influenza Vaccines in the Clinical Development
17. Influenza Vaccines Clinical Trial Insights by Phase, Company and Country
17.1 Year 2024
17.2 Year 2023
17.3 Year 2022
17.4 Year 2021
18. Key Company Profiles
18.1 Sanofi Pasteur
18.1.1 Business Overview
18.1.2 Influenza Vaccines Portfolio
18.1.3 Influenza Vaccines Sales Value Analysis
18.1.4 Promising Influenza Vaccines in the Clinical Development
18.1.5 Recent Development
18.2 GlaxoSmithKline (GSK)
18.3 Seqirus
18.4 AstraZeneca
19. Emerging Company Profiles
19.1 Novavax
19.1.1 Business Overview
19.1.2 Promising Influenza Vaccines in the Clinical Development
19.1.3 Recent Development
19.2 BiondVax Pharmaceuticals Ltd.
19.3 Medicago
19.4 Moderna Inc
19.5 Pneumagen
19.6 Altimmune
19.7 Daiichi Sankyo
19.8 FluGen
19.9 Imutex
19.10 EpiVax
19.11 Versatope Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/iu4j3v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
